Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
Chalmers University of Technology spin out takes a different route to cancer biomarker identification
Executive Summary
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
You may also be interested in...
Royal Philips’ IGT Goes For The Structural Heart
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.
Royal Philips’ IGT Goes For The Structural Heart
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.
The Big Health Care Conundrum: How To Sustainably Unlock The Value Of Diagnostics
With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.